{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:25:24Z","timestamp":1762431924840,"version":"build-2065373602"},"reference-count":48,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major proportion of MM patients will relapse, underscoring the need for new therapies in this disease. Moreover, survival in patients failing the current standard of care regimens (including PI, IMIDs, and anti-CD38 MoAb), which is now defined as triple-class refractory, remains dismal, and new drugs with different mechanism of action are needed. B-cell maturation antigen (BCMA)-targeted therapies and in particular chimeric antigen receptor T cell (CAR T-cell) treatment have emerged as promising platforms to overcome refractoriness to conventional drugs. In this manuscript, we review the current available data regarding CAR T-cell therapy for MM, with a special focus on target selection, clinical results, limitations, and future strategies.<\/jats:p>","DOI":"10.3390\/jcm9113577","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:03:04Z","timestamp":1604653384000},"page":"3577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["CAR T-Cells in Multiple Myeloma Are Ready for Prime Time"],"prefix":"10.3390","volume":"9","author":[{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"first","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de investigaci\u00f3n m\u00e9dica aplicada (Cima), CIBERONC, IDISNA, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Pr\u00f3sper","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de investigaci\u00f3n m\u00e9dica aplicada (Cima), CIBERONC, IDISNA, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Alfonso","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de investigaci\u00f3n m\u00e9dica aplicada (Cima), CIBERONC, IDISNA, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de investigaci\u00f3n m\u00e9dica aplicada (Cima), CIBERONC, IDISNA, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas F. San","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de investigaci\u00f3n m\u00e9dica aplicada (Cima), CIBERONC, IDISNA, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.192.11.1677","article-title":"A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell Growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","article-title":"The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker","volume":"18","author":"Sanchez","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_11","first-page":"3473","article-title":"CAR T-cell therapy: Is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e127684","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood-2019-129740","article-title":"Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study","volume":"134","author":"Yan","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/onc.2008.272","article-title":"NKG2D ligands in tumor immunity","volume":"27","author":"Nausch","year":"2008","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2018-99-114522","article-title":"NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells","volume":"132","author":"Leivas","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","unstructured":"Usmani, S.Z., Deepu, M., Berdeja, J.G., Indrajeet, S., Zudaire, E., Yeh, T.-M., Allred, A.J., Olyslager, Y., Banerjee, A., and Goldberg, J.D. (2020). Treatment of Relapsed\/Refractory Multiple Myeloma with Jnj-4528, A B-Cell Maturation Antigen (Bcma)-Directed Chimeric Antigen Receptor (Car)-T Cell Therapy: Update of Phase 1b Results from Cartitude-1, EHA Library."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2019-130008","article-title":"Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood.V126.23.LBA-1.LBA-1","article-title":"Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor","volume":"126","author":"Ali","year":"2015","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","article-title":"Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"132","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1200\/JCO.2020.38.15_suppl.8525","article-title":"KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa","volume":"38","author":"Jagannath","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2019-127309","article-title":"Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b\/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and\/or Refractory Multiple Myeloma (R\/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset","volume":"134","author":"Zudaire","year":"2019","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"ref_39","unstructured":"Da-Via, M., Dietrich, O., Truger, M., Arampatzi, P., Duell, J., Zhou, X., Tabares, P., Danhof, S., Kraus, S., and Meggendorfer, M. (2020). Biallelic Deletion of Chromosome 16p Encompassing the BCMA Locus as a Tumor-Intrinsic Resistance Mechanism to BCMA-Directed CAR T in Multiple Myeloma, EHA Library Rasche L."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref_41","first-page":"7126","article-title":"PiggyBac transposon system with polymeric gene carrier transfected into human T cells","volume":"11","author":"Zheng","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.beha.2020.101141","article-title":"CAR T and CAR NK cells in multiple myeloma: Expanding the targets","volume":"33","author":"Shah","year":"2020","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_43","first-page":"3068","article-title":"B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-\/- and Patient-Derived Multiple Myeloma Tumors","volume":"130","author":"Mathur","year":"2017","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood.V126.23.116.116","article-title":"Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa\/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)","volume":"126","author":"Galetto","year":"2015","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2018-99-116443","article-title":"Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma","volume":"132","author":"Dar","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric Antigen Receptor-T Cell Therapy","volume":"2","author":"Buechner","year":"2018","journal-title":"HemaSphere"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:30:08Z","timestamp":1760178608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113577"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113577","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,11,6]]}}}